NL-OMON20474已完成不适用
High-dose, pulsatile erlotinib after progression on standard dose erlotinib in EGFR-mutated NSCLC patients.
VU Medical Center0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically confirmed stage IV non-squamous NSCLC patients;
- •2. Patients with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy in daily dose of 150 mg or 250 mg respectively. (Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible);
排除标准
- •1. No uncontrolled infectious disease;
- •2. No other active malignancy;
研究者
相似试验
已完成
2 期
High-dose, pulsatile erlotinib after progression on standard dose erlotinib in EGFR-mutated NSCLC patients10038666Lung cancerNL-OMON36916Vrije Universiteit Medisch Centrum50
招募中
2 期
Phase II study of erlotinib in advanced or recurrent EGFR mutation positive Non-small cell lung cancer patients who were previously treated with intrapleural therapy for malignant pleural effusion.on-small cell lung cancerJPRN-UMIN000006518Kitasato university hospital35
进行中（未招募）
不适用
Concomitant Radiotherapy and Erlotinib in advanced lung cancerThoRaT-studienThoracal Radiotherapy and Tarceva®An open randomized multicenter phase II studyon-small cell lung cancer, - palliative treatmentEUCTR2012-000967-25-NO
已完成
不适用
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40
Unknown
2 期
The Continuation of ErlotinibNon-small Cell Lung CancerNCT01130779Samsung Medical Center23